top of page
Transforming the Treatment of
Emotional and Behavioral Dysregulation
A clinical-stage precision psychiatry company developing brain-engaged therapies to restore emotional and behavioral control across severe CNS disorders.
A Major Unmet Need Across CNS disorders
Severe emotional and behavioral dysregulation — including irritability, agitation, aggression, and impulse control — is a core driver of disability, caregiver burden, and healthcare cost across multiple CNS disorders.
Despite the scale of the problem, there are no safe, effective, long-term therapies designed to address the underlying biology of behavioral dyscontrol.
Distinct CNS disorders converge on shared monoaminergic circuit dysfunction.
Core Dysfunction: Monoaminergic Imbalance (5-HT, DA, NE)
Serotonin (5-HT)
Emotional regulation, aggression
Dopamine (DA)
Reward & impulse control
Norepinephrine (NE)
Arousal, anxiety, & stress response
ConSynance is built on the insight that restoring balanced serotonin, dopamine, and norepinephrine signaling can address pathological behavioral dyscontrol across a spectrum of conditions — from genetically defined neurodevelopmental disorders to common neuropsychiatric and neurodegenerative diseases.
One Core Biological Imbalance. Multiple Disorders.
This shared biology enables a single therapeutic platform with multiple, independently validated development paths.
bottom of page